Analysts Issue Forecasts for Dare Bioscience Q2 Earnings

Dare Bioscience, Inc. (NASDAQ:DARE) – Investment analysts at HC Wainwright issued their Q2 2026 earnings per share estimates for shares of Dare Bioscience in a research report issued on Friday, May 15th. HC Wainwright analyst D. Tsao forecasts that the biotechnology company will post earnings of ($0.25) per share for the quarter. The consensus estimate for Dare Bioscience’s current full-year earnings is ($1.50) per share. HC Wainwright also issued estimates for Dare Bioscience’s Q3 2026 earnings at $0.09 EPS, Q4 2026 earnings at ($0.20) EPS, FY2026 earnings at ($0.57) EPS, FY2027 earnings at ($0.45) EPS, FY2028 earnings at $0.01 EPS and FY2029 earnings at $1.17 EPS.

Dare Bioscience (NASDAQ:DARE) last posted its quarterly earnings results on Thursday, May 14th. The biotechnology company reported ($0.20) EPS for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.13. The business had revenue of $0.15 million during the quarter, compared to analysts’ expectations of $0.03 million.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Dare Bioscience in a report on Monday, April 20th. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $10.00.

Dare Bioscience Trading Down 2.8%

NASDAQ DARE opened at $2.11 on Tuesday. The stock’s 50 day moving average is $2.00 and its 200 day moving average is $1.92. Dare Bioscience has a 12 month low of $1.27 and a 12 month high of $9.19. The stock has a market cap of $31.61 million, a PE ratio of -2.22 and a beta of 1.09.

Institutional Trading of Dare Bioscience

Several hedge funds have recently modified their holdings of DARE. LPL Financial LLC purchased a new stake in shares of Dare Bioscience during the 4th quarter worth approximately $28,000. Raymond James Financial Inc. raised its holdings in shares of Dare Bioscience by 810.6% during the 3rd quarter. Raymond James Financial Inc. now owns 15,334 shares of the biotechnology company’s stock worth $32,000 after acquiring an additional 13,650 shares in the last quarter. Finally, Virtu Financial LLC purchased a new stake in shares of Dare Bioscience during the 3rd quarter worth approximately $37,000. 6.70% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Dare Bioscience

Here are the key news stories impacting Dare Bioscience this week:

• Positive Sentiment: Brookline Capital Markets raised its FY2026 EPS estimate for Dare Bioscience, suggesting slightly improved near-term expectations for the women’s health biotech. DARE stock page
• Positive Sentiment: HC Wainwright’s long-range outlook was constructive, with estimates showing a path to profitability in later years, including positive EPS projected for FY2028 and FY2029. DARE stock page
• Neutral Sentiment: The company announced it has started a Phase 2 study of DARE-HPV, a treatment for persistent high-risk HPV infection, backed by a $10 million ARPA-H-funded contract. The trial is an important pipeline update, but topline data is not expected until 2027, so the near-term stock impact is likely limited. Article: Daré Bioscience Initiates Phase 2 Study of DARE-HPV
• Negative Sentiment: Several analyst updates still point to expected losses in 2026 and 2027, reinforcing that Dare Bioscience remains far from consistent profitability. DARE stock page

Dare Bioscience Company Profile

Dare Bioscience, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for women’s reproductive health. The company’s flagship development candidate is Ovaprene, a monthly, self-administered, non-hormonal contraceptive vaginal ring designed to offer an alternative to traditional hormone-based birth control methods. Through its proprietary intravaginal drug delivery platform, Dare seeks to address unmet medical needs in gynecology and contraception with products that prioritize efficacy, safety and ease of use.

In addition to its lead contraceptive program, Dare is advancing a pipeline of early-stage assets aimed at treating gynecologic conditions through local, non-systemic drug delivery.